Topical loperamide for the treatment of localized neuropathic pain: a case report and literature review

Abstract: Peripheral nerve damage can result in neuronal hyperexcitability, resulting in neuropathic pain. Localized neuropathic pain is confined to a specific area not larger than a letter-size piece of paper. Topical analgesics are increasingly popular for the treatment of localized neuropathic pain because systemic agents for managing neuropathic pain often produce undesirable and intolerable side effects. Commonly used agents for topical use are amitriptyline, baclofen, ketamine and lidocaine; however, these agents do not always give the desired analgesic effect in some patients. We report for the first time a patient with chronic idiopathic axonal polyneuropathy and intractable localized neuropathic pain treated successfully with loperamide 5% cream. After application of loperamide 5% cream, the patient reported a complete reduction of pain within 30 mins, lasting for 2.5 hrs. Subsequently, the patient was able to reduce his daily intake of oxycodone, while using topical loperamide for pain relief. Loperamide is a nonprescription opioid agonist, commonly used against diarrhea. As a topical formulation, it is preferable over other opioids due to its low systemic bioavailability and low risk of crossing the blood–brain barrier. Peripheral upregulation and sensitization of opioid receptors at peripheral nerve endings and perhaps at other cell populations in the epidermis might be targets of topical loperamide.

Keywords: localized neuropathic pain, loperamide, topical agents, analgesia

Introduction
Peripheral nerve damage can result in neuronal hyperexcitability, resulting in neuropathic pain.1 Peripheral nerves can be affected by metabolic damage, toxins and medications.1 Localized neuropathic pain (LNP) is confined to a specific area not larger than a letter-size piece of paper.2 Averaging across all neuropathic pain conditions approximately 60% of the patients have LNP.2 Topical analgesics are becoming increasingly popular with most patients for the treatment of LNP, because nearly no side effects are present when used properly. Neuropathic pain agents taken orally for analgesia target the central nervous system (CNS), commonly produce undesirable and often unacceptable side effects.3 These CNS side effects include somnolence, sedation, confusion and cognitive disturbances. Other side effects, particularly with gabapentinoids, include weight-gain, and some patients report intolerance to the dryness of mouth and drowsiness from the tricyclic antidepressants such as amitriptyline. Hyperhidrosis, nausea, dry mouth, fatigue and gastrointestinal disturbances have been reported as reasons for patients discontinuing serotonin–norepinephrine reuptake inhibitors like duloxetine.4,5
comparison to systemic agents, compounded topical preparations of such agents are well tolerated by patients. Most patients respond well to commonly used topical agents like amitriptyline, ketamine, clonidine, lidocaine and baclofen (see Table 1 for known topical analgesics the treatment of neuropathic pain). However, there are still patients who would not have a favorable analgesic response with these agents. In such patients with intractable pain not responding to more obvious topical analgesics, other treatment strategies have to be explored.

In this report, we describe a case of chronic idiopathic axonal polyneuropathy (CIAP) with intractable LNP treated successfully with topical application of loperamide 5% cream. CIAP is a slowly progressive distal symmetric sensory or sensorimotor polyneuropathy without a known cause, and approximately one-third of the patients have neuropathic pain in the feet sometimes extending into the lower legs. In neuropathic pain mice models, the concentration of μ-opioid receptors (MOR) was elevated the skin. Therefore, we chose loperamide topically as a nonprescription MOR agonist used for the symptomatic management of diarrhea.

After oral intake, loperamide is well absorbed from the gastrointestinal tract and is almost completely extracted and metabolized by cytochrome P450 (particularly CYP3A4) in the liver. As a result, the bioavailability after oral intake is only around 0.3%. Loperamide has a considerably higher binding affinity to the MOR than to the δ-opioid receptor (DOR) or the κ-opioid receptor (KOR), with \( K_i \) values of 3.3, 48 and 1156 nM, respectively. The higher binding affinity a drug has to a receptor, the more the drug influences the receptor. Although loperamide is highly lipophilic, the efflux membrane transporter in the blood–brain barrier, P-glycoprotein, actively extrudes loperamide from the CNS. The use of topical loperamide for the treatment of peripheral neuropathic pain has never been described in published literature. The patient has given his written informed consent, and no institutional approval is required to publish his case anonymously.

### Case report

A 63-year-old man suffered from neuropathic pain due to CIAP since 2013. The pain started in the distal parts of both feet, where the size of the pain area gradually expanded over time, up to 10 cm above the ankles in the following years. He scored 8 out of 10 on the Douleur Neuropathique 4 questionnaire (DN-4), which indicated that clinical signs and symptoms were of neuropathic nature and origin. In his own words, the patient characterized the pain as burning, tingling, pins and needles, electric shocks and numbness. Despite being on analgesics and neuropathic pain agents, he scored his pain intensity as 7 on the 11-point numerical rating scale (NRS). At that time, he used amitriptyline 25 mg once daily and oxycodone 10 mg twice daily. Oxycodone 10 mg only reduced his pain temporarily. Previously, pregabalin and neuraxial blockade at L4 and L5 did not have any effect on the pain. In addition to his severe pain, it was noticed that his sense of maintaining balance was poor. Physical examination further revealed loss of vibration sense up to both knees, absence of bilateral ankle jerk reflexes, loss of temperature discrimination, hypoaesthesia for pinprick and touch and allodynia after soft stroking with a hand up to a length of 20 cm beneath the knees. Baclofen 5% cream and amitriptyline 10% cream reduced his pain from a score of 7 to 5 on the NRS, but the patient did not feel this provided him adequate and meaningful analgesia. On consultation, a single-blind response test with amitriptyline 10% cream on the right foot and loperamide 5% cream on the left foot was performed.

<table>
<thead>
<tr>
<th>Agents</th>
<th>Concentration in %</th>
<th>Main mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambroxol</td>
<td>20</td>
<td>TTX-resistant sodium channel blocker</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>1, 2, 5, 10</td>
<td>Inhibition of sodium, potassium, calcium voltage-gated ion channels</td>
</tr>
<tr>
<td>Baclofen</td>
<td>2, 5</td>
<td>GABA-B receptor agonist</td>
</tr>
<tr>
<td>Capsaicin</td>
<td>0.025–0.075, 8</td>
<td>Desensitization of transient receptor</td>
</tr>
<tr>
<td>Clonidine</td>
<td>0.1, 0.2</td>
<td>Potential vanilloid 1 channel</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>6</td>
<td>α2-adrenergic agonists</td>
</tr>
<tr>
<td>Ketamine</td>
<td>0.5, 1, 1.5, 2, 10</td>
<td>Inhibition of α2δ subunits of calcium channels</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>2, 3, 5, 8, 10</td>
<td>Inhibition of glutamate N-methyl-D-aspartate receptor</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>5, 10, 20, 30</td>
<td>Stabilization of voltage-gated sodium channels</td>
</tr>
</tbody>
</table>

Table 1 (Co)-analgesics and their concentrations alone or in combinations in topical formulations
cream on the left foot was performed. After 30 mins, the patient reported a pain reduction of 7 to 5 on the NRS on the amitriptyline 10% cream applied area and a reduction from 7 to 3 on the loperamide 5% cream applied area. Because loperamide 5% cream had clearly a more pain reducing effect, loperamide 5% cream was prescribed.

Following a period of 3 days of open test application with loperamide 5% cream, in a telephone call, the patient reported back that the neuropathic pain was completely resolved. The onset of the analgesic effect was within 30 mins of initial application. Over the course of the following weeks, the patient applied loperamide 5% cream once or twice daily for symptomatic relief and the pain-reducing effect lasted for about 2.5 hrs following each application. More daily applications were not practical. Due to the positive and meaningful reduction of the pain, the patient could reduce his oral oxycodone intake by 50%. The patient did not report nor experience any side effects from the topical application of loperamide 5% cream.

Discussion

The authors feel that to the best of our knowledge, we have described the first case of LNP treated successfully with topical loperamide 5% cream as a single agent. Single-blind response test (SIBRET) performed with amitriptyline 10% cream and loperamide 5% cream showed the superiority of loperamide 5% cream over amitriptyline 10% cream in this patient. When testing the effect in naïve patients with topical analgesics, SIBRET with placebo cream is preferable to rule out initial placebo responders. There is a case report of one patient with complex regional pain syndrome pain successfully treated with topical application of a combination gel consisting of ketamine 15%/loperamide 5%/guaifenesin 10%/lidocaine 2%.19 For the management of acute pain due to finger lancing, loperamide 5% gel has been evaluated in a double-blind randomized clinical trial (NCT02711891).20 In this study, 34 adult volunteers received 2 lancings. Ten minutes following the first lance, loperamide 5% gel or placebo gel was applied onto the lanced fingertips. A repeat lance followed in 30 mins. Loperamide 5% gel produced a statistically significant decrease in visual analogue scale (VAS) (1.9±1.4 vs 4.2±2.4 p=0.002) as compared to the placebo gel. At 24 hrs, the proportion of participants who stated no pain (loperamide 82%, placebo 29%), no sensitivity to light touch (loperamide 82%, placebo 35%) and no sensitivity to pressure (loperamide 88%, placebo 29%) were significantly greater in the loperamide 5% gel group.

Results from one animal study indicate that loperamide creams with the concentration of 0.5%, 1.7% and 5% had a dose-dependent anti-hyperalgesic effect in a thermal injury rat model.21 In a second animal study, using a full-thickness burn rat model, topical loperamide 5% significantly increased mechanical thresholds, prevented sensitization of uninjured skin and reduced burn-induced ectopic discharge of the recorded nociceptive fibers.22 The mechanism of action of topical loperamide in peripheral neuropathic pain is most probably by influencing MORs at the nerve endings of the nociceptors, and perhaps additionally, on other structures in the epidermis (for example, keratinocytes and immune-competent cells).23 In several neuropathic pain models, an enhanced expression of opioid receptors has been documented at the nerve lesion site and in paw skin.24 Our postulation is that topical loperamide acts on MORs at nociceptors in the skin and other cell-populations such as keratinocytes and immune-competent cells. Topical loperamide 5% formulation might be a new useful addition as a potential therapeutic option in the treatment of therapy-resistant LNP. The optimal concentration of loperamide cream will have to be elucidated in N-of-1 studies and/or dose-finding studies.

Conclusion

In our case report, loperamide 5% cream proved effective in reducing intractable neuropathic pain which did not respond to systemic analgesics and other trials of topical agents. Clinicians facing patients with intractable LNP, not responding on oral analgesics or common compounded topical analgesics, can broaden their armamentarium with topical loperamide. The use of SIBRET in symmetrical polyneuropathy to determine true responders on topical loperamide can be very helpful.25 Well-designed double-blinded randomized controlled trials will further elucidate the role of topical loperamide as an option for the management of LNP.

Disclosure

DJ Kopsky and Prof. Dr JM Keppel Hesselink report patents pending on topical phenytoin. The authors report no other conflicts of interest in this work.
References


